Shipra Rastogi

RECENT SCHOLAR PUBLICATIONS

Biophotonic compositions and methods for providing biophotonic treatment
R Piergallini, N Loupis, S Rastogi
US Patent App. 18/366,224 , 2024
2024
Biophotonic compositions and methods for providing biophotonic treatment
R Piergallini, N Loupis, S Rastogi
US Patent 11,723,854 , 2023
2023
Biophotonic compositions and methods for providing biophotonic treatment
R Piergallini, N Loupis, S Rastogi
US Patent 11,331,257 , 2022
2022
Citations: 1
Biophotonic compositions, kits and methods
N Loupis, R Piergallini, S Rastogi
US Patent 11,116,841 , 2021
2021
Citations: 17
Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds
N Loupis, R Piergallini, S Rastogi
US Patent App. 17/130,587 , 2021
2021
Citations: 1
Biophotonic compositions comprising a chromophore and a gelling agent for treating wounds
N Loupis, R Piergallini, S Rastogi
US Patent 10,881,736 , 2021
2021
Citations: 1
Biophotonic compositions and methods for providing biophotonic treatment
R Piergallini, N Loupis, S Rastogi
US Patent 10,376,455 , 2019
2019
Citations: 6
Efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis and skin of color: results from the pooled AMAGINE-2/-3 randomized trials
A McMichael, SR Desai, A Qureshi, S Rastogi, AF Alexis
American journal of clinical dermatology 20 (2), 267-276 , 2019
2019
Citations: 39
Brodalumab in patients who had inadequate response to ustekinumab
RG Langley, AW Armstrongi, MG Lebwohl, A Blauvelt, S Hsu, S Tyring, ...
British Journal of Dermatology 180, 306-314 , 2019
2019
Citations: 3
Brodalumab 用于对乌司奴单抗应答不足的患者
RG Langley, AW Armstrongi, MG Lebwohl, A Blauvelt, S Hsu, S Tyring, ...
British Journal of Dermatology 180 (2), e53-e53 , 2019
2019
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials
RG Langley, AW Armstrong, MG Lebwohl, A Blauvelt, S Hsu, S Tyring, ...
British Journal of Dermatology 180 (2), 306-314 , 2019
2019
Citations: 41
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
JJ Wu, SR Feldman, S Rastogi, B Menges, M Lingohr-Smith, J Lin
Journal of Dermatological Treatment 29 (8), 769-774 , 2018
2018
Citations: 60
Improvement in nail psoriasis with brodalumab treatment over 52 weeks: An analysis of two phase 3 studies: 6448
B Elewski, L Green, S Rastogi, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB162 , 2018
2018
Citations: 4
Long-term safety of brodalumab for the treatment of moderate-to-severe psoriasis: Two-year data from 3 pivotal phase 3 clinical trials: 6402
KA Papp, JM Sobell, S Tyring, S Rastogi, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB181 , 2018
2018
Citations: 3
Retreatment with brodalumab results in high response rates in patients with psoriasis after treatment interruption: 6841
A Armstrong, A Blauvelt, JJ Wu, BR Keegan, S Rastogi, R Pillai, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB246 , 2018
2018
Citations: 2
Efficacy of brodalumab in patients with previous biologic exposure and inadequate response to ustekinumab: 6837
A Armstrong, S Hsu, M Lebwohl, J Sobell, S Rastogi, R Pillai, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB123 , 2018
2018
Efficacy and safety of brodalumab versus ustekinumab in obese and nonobese patients with moderate-to-severe plaque psoriasis: 6834
P Yamauchi, B Elewski, JJ Wu, S Rastogi, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB119 , 2018
2018
Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials: 6616
M Lebwohl, KA Papp, S Tyring, J Krueger, S Rastogi, R Pillai, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB180 , 2018
2018
Citations: 5
Long-term efficacy of brodalumab in ustekinumab-responsive patients with moderate-to-severe psoriasis: 6832
L Green, S Hsu, KA Papp, S Rastogi, R Pillai, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB181 , 2018
2018
Citations: 1
Efficacy and safety of brodalumab in patients with inadequate response to ustekinumab: Analysis of two phase 3 psoriasis studies: 6027
A Blauvelt, S Tyring, R Langley, S Rastogi, R Pillai, RJ Israel
Journal of the American Academy of Dermatology 79 (3), AB119 , 2018
2018
Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

Nicotine induces cell proliferation, invasion and epithelial‐mesenchymal transition in a variety of human cancer cell lines
P Dasgupta, W Rizwani, S Pillai, R Kinkade, M Kovacs, S Rastogi, ...
International Journal of Cancer 124 (1), 36-45 , 2009
2009
Citations: 471
Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling
G Fusaro, P Dasgupta, S Rastogi, B Joshi, S Chellappan
Journal of Biological Chemistry 278 (48), 47853-47861 , 2003
2003
Citations: 468
Nicotine induces cell proliferation by β-arrestin–mediated activation of Src and Rb–Raf-1 pathways
P Dasgupta, S Rastogi, S Pillai, D Ordonez-Ercan, M Morris, E Haura, ...
The Journal of clinical investigation 116 (8), 2208-2217 , 2006
2006
Citations: 392
Detection of aflatoxin M1 contamination in milk and infant milk products from Indian markets by ELISA
S Rastogi, PD Dwivedi, SK Khanna, M Das
Food control 15 (4), 287-290 , 2004
2004
Citations: 341
Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials
MG Lebwohl, KA Papp, LB Marangell, J Koo, A Blauvelt, M Gooderham, ...
Journal of the American Academy of Dermatology 78 (1), 81-89. e5 , 2018
2018
Citations: 202
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines
S Rastogi, S Banerjee, S Chellappan, GR Simon
Cancer letters 257 (2), 244-251 , 2007
2007
Citations: 168
Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells
AV Timoshenko, S Rastogi, PK Lala
British journal of cancer 97 (8), 1090-1098 , 2007
2007
Citations: 142
Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes
S Rastogi, B Joshi, P Dasgupta, M Morris, K Wright, S Chellappan
Molecular and cellular biology 26 (11), 4161-4171 , 2006
2006
Citations: 117
Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism
S Rastogi, B Joshi, G Fusaro, S Chellappan
Journal of Biological Chemistry 281 (5), 2951-2959 , 2006
2006
Citations: 109
TNF-α response of vascular endothelial and vascular smooth muscle cells involve differential utilization of ASK1 kinase and p73
S Rastogi, W Rizwani, B Joshi, S Kunigal, SP Chellappan
Cell Death & Differentiation 19 (2), 274-283 , 2012
2012
Citations: 105
Protective effect of Ocimum sanctum on 3-methylcholanthrene, 7, 12-dimethylbenz (a) anthracene and aflatoxin B1 induced skin tumorigenesis in mice
S Rastogi, Y Shukla, BN Paul, DK Chowdhuri, SK Khanna, M Das
Toxicology and applied pharmacology 224 (3), 228-240 , 2007
2007
Citations: 99
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the …
KA Papp, KB Gordon, RG Langley, MG Lebwohl, AB Gottlieb, S Rastogi, ...
British Journal of Dermatology 179 (2), 320-328 , 2018
2018
Citations: 81
Differential regulation of human YY1 and caspase 7 promoters by prohibitin through E2F1 and p53 binding sites
B Joshi, S Rastogi, M Morris, LM Carastro, C DeCook, E Seto, ...
Biochemical Journal 401 (1), 155-166 , 2007
2007
Citations: 67
Skin tumorigenic potential of aflatoxin B1 in mice
S Rastogi, RKS Dogra, SK Khanna, M Das
Food and Chemical Toxicology 44 (5), 670-677 , 2006
2006
Citations: 65
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States
JJ Wu, SR Feldman, S Rastogi, B Menges, M Lingohr-Smith, J Lin
Journal of Dermatological Treatment 29 (8), 769-774 , 2018
2018
Citations: 60
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 …
A Blauvelt, KA Papp, MG Lebwohl, LJ Green, S Hsu, V Bhatt, S Rastogi, ...
Journal of the American Academy of Dermatology 77 (2), 372-374 , 2017
2017
Citations: 60
Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX
MI Niesen, AR Osborne, H Yang, S Rastogi, S Chellappan, JQ Cheng, ...
Journal of Biological Chemistry 280 (47), 38914-38922 , 2005
2005
Citations: 57
Direct binding of apoptosis signal-regulating kinase 1 to retinoblastoma protein: novel links between apoptotic signaling and cell cycle machinery
P Dasgupta, V Betts, S Rastogi, B Joshi, M Morris, B Brennan, ...
Journal of Biological Chemistry 279 (37), 38762-38769 , 2004
2004
Citations: 53
A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light …
JSS Andreas Nikolis, Steven Bernstein, Brian Kinney, Nicolo Scuderi, Shipra ...
Clinical, Cosmetic and Investigational Dermatology 9, 115-125 , 2016
2016
Citations: 43
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials
RG Langley, AW Armstrong, MG Lebwohl, A Blauvelt, S Hsu, S Tyring, ...
British Journal of Dermatology 180 (2), 306-314 , 2019
2019
Citations: 41